Getinge AB (GNGBY)
OTHER OTC:GNGBY
Top Page
Getinge AB
(OTC:GNGBY)
Select Model
Select Model
Rating:59Neutral
Price Target:
$20.50
▼(-10.75% Downside)
Action:ReiteratedDate:01/30/26
The score is driven primarily by stable-but-moderating financial performance (solid balance sheet, but weaker growth/margins and volatile/downshifting free cash flow). Technical indicators are notably weak and weigh on the result. Valuation is average (P/E ~26 with a modest yield). Earnings call signals are constructive on guidance and underlying margin trajectory, but ongoing tariff/FX pressure and execution risks (delays and quality costs) keep the overall score in the high-50s.
Positive Factors
Strong balance sheet / manageable leverage
Getinge's balance sheet shows moderate leverage (debt-to-equity ~0.27–0.37) and net debt metrics that management reports as manageable. This financial flexibility supports continued R&D, product launches, dividend payments and withstands cyclical shocks, reducing refinancing and solvency risk over the medium term.
Negative Factors
Material tariff and FX headwinds
Persistent tariffs (~SEK 370m in 2025) and FX effects that together trimmed over SEK 1bn of adjusted EBITDA are structural near-term headwinds. These external cost pressures compress reported margins, limit operating leverage benefits and force price/productivity actions that can take quarters to fully offset.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / manageable leverage
Getinge's balance sheet shows moderate leverage (debt-to-equity ~0.27–0.37) and net debt metrics that management reports as manageable. This financial flexibility supports continued R&D, product launches, dividend payments and withstands cyclical shocks, reducing refinancing and solvency risk over the medium term.
Read all positive factors
Getinge AB (GNGBY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.55B
Dividend Yield2.05%
Average Volume (3M)149.00
Price to Earnings (P/E)26.3
Beta (1Y)0.63
Revenue Growth10.70%
EPS Growth27.42%
CountryUS
Employees11,827
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.34
Shares Outstanding254,152,370
10 Day Avg. Volume133
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)2.02
Price to Sales (P/S)1.70
P/FCF Ratio23.97
Enterprise Value/Market Cap10.72
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda9.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Getinge AB Business Overview & Revenue Model
Company Description
Getinge AB is a global medical technology company based in Sweden, specializing in advanced solutions for healthcare professionals in the hospital and life sciences sectors. The company operates primarily in three areas: Surgical Workflows, Critic...
How the Company Makes Money
Getinge makes money primarily by selling medical technology products and related services across two main areas: (1) hospital-focused solutions and (2) life science solutions. Revenue is generated from: (a) capital equipment sales—larger-ticket sy...
Getinge AB Earnings Call Summary
Earnings Call Date:Jan 27, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 21, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive picture: underlying operational performance, recurring revenue mix, product launches, regulatory progress and a strong balance sheet are clear positives. However, significant external headwinds — notably tariffs and currency moves — materially suppressed reported margins and profitability in 2025 and are expected to persist into 2026. Additionally, softness in parts of Life Science, supply delays for CardioSave and elevated quality‑related costs temper near‑term visibility. Management is confident in mitigation actions and progression toward the mid‑term margin target, but the combination of solid fundamentals and notable external pressures results in a balanced outlook.Positive Updates
Record quarter with organic revenue growth
Q4 organic net sales grew by 1.2% versus prior year, beating last year's record quarter; order intake increased organically by 2.3%.
Negative Updates
Significant FX and tariff headwinds
Tariffs and currency were a material drag — more than SEK 1 billion negative impact on adjusted EBITDA for 2025, with tariffs ≈ SEK 370 million for the full year and ≈ SEK 150 million in Q4; combined tariff/currency headwind in Q4 was nearly SEK 500 million.
Read all updates
Q4-2025 Updates
Positive
Negative
Record quarter with organic revenue growth
Q4 organic net sales grew by 1.2% versus prior year, beating last year's record quarter; order intake increased organically by 2.3%.
Read all positive updates
Company Guidance
Getinge guided to organic net sales growth of 3–5% for 2026 (adjusted for the phaseout of Surgical Perfusion, which is expected to fall from ~SEK 250m to ~SEK 50m), while reiterating its mid‑term adjusted EBITA target of 16–19% by end‑2028; management said tariffs and FX will remain a headwind (tariffs cost ~SEK 370m in 2025 and ~SEK 150m in Q4, with at least ~SEK 0.5bn expected in 2026, and FX hit Q4 by ~1.2 percentage points), but underlying performance is strong—Q4 adjusted gross profit was SEK 5.037bn, adjusted EBITDA SEK 1.809bn (17.8% margin), free cash flow SEK 1.2bn, net debt SEK 9.8bn (SEK 7.5bn excl. pensions) with leverage 1.5x (1.1x excl. pensions) and cash ~SEK 3.4bn—and management expects to mitigate headwinds via ~2% price increases, productivity actions and regulatory/product launches (CardioSave 510(k) now expected in Q2 2026; Cardiohelp II CE submission made Q4 2025 with EU shipments early‑2026 and US 510(k) H2 2026), while extraordinary quality costs should decline from H2 2026 and be much lower in 2027–28; the Board proposed a dividend of SEK 4.75 per share.Getinge AB Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
74
Positive
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 16.65B | 16.15B | 14.49B | 13.41B | 13.58B |
| EBITDA | 6.44B | 5.31B | 5.91B | 5.70B | 6.15B |
| Net Income | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | |||||
| Total Assets | 56.51B | 63.92B | 53.59B | 52.03B | 44.55B |
| Cash, Cash Equivalents and Short-Term Investments | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 27.01B | 30.71B | 23.18B | 21.58B | 19.38B |
| Stockholders Equity | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | |||||
| Free Cash Flow | 2.48B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 3.71B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.78B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -719.09M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge AB Technical Analysis
Neutral
22.97
Price Trends
21.53
Negative
22.27
Negative
21.85
Negative
Market Momentum
-0.51
Negative
50.89
Neutral
78.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Neutral. The current price of 22.97 is above the 20-day moving average (MA) of 20.20, above the 50-day MA of 21.53, and above the 200-day MA of 21.85, indicating a neutral trend. The MACD of -0.51 indicates Negative momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 78.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GNGBY.
Getinge AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $13.57B | 22.70 | 11.79% | 2.28% | 5.78% | 61.52% | |
69 Neutral | $21.57B | 32.31 | 10.21% | 0.94% | 5.15% | 60.30% | |
68 Neutral | $14.57B | 80.92 | 17.36% | ― | 27.12% | -41.72% | |
65 Neutral | $17.81B | 25.25 | 5.60% | 1.05% | 5.47% | -23.03% | |
64 Neutral | $25.92B | 24.78 | 8.21% | 3.30% | -0.76% | -55.03% | |
59 Neutral | $5.55B | 26.30 | 7.66% | 2.05% | 10.70% | 27.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GNGBY
Getinge AB
20.63
-0.27
-1.29%
PODD
Insulet
207.04
-49.76
-19.38%
PHG
Koninklijke Philips
27.29
4.15
17.92%
SNN
Smith & Nephew Snats
32.09
4.77
17.46%
STE
Steris
219.94
0.72
0.33%
ZBH
Zimmer Biomet Holdings
91.03
-20.46
-18.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.